Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scancell Ltd.

www.scancell.co.uk

Latest From Scancell Ltd.

Appointments: BMS, Scancell, Zafgen, Cell Medica, Silence Therapeutics, Malin and Trillium

This week's roundup includes CEO appointments by Gadeta, Scancell and Zafgen, with various other high-level appointments by Malin Corporation, Cell Medica and Apeiron Biologics.

Appointments BioPharmaceutical

Pipeline Watch: Phase III Starts In MS, Hyperkalemia And Short Stature

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Research & Development Pipeline Watch

Scancell names development director

Scancell, which develops immunotherapies for the treatment of cancer, has appointed Dr Sally Adams to its board of directors as development director – effective 1 May 2014. Dr Adams has worked as a consultant at Nottingham, UK-based Scancell since 2008. Previously, she was head of neurology and virology at British Biotech, and development director at Neures.

Cancer

In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines

With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Scancell Ltd.
  • Senior Management
  • Richard Goodfellow, PhD, Joint CEO
    Sally Adams, PhD, Dev Director
  • Contact Info
  • Scancell Ltd.
    Phone: (44) 115 823 1863
    City Hospital - Dept. of Clin. Oncology
    Hucknall Rd.
    P.O. Box 6457 Nottingham, NG5 1PB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register